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Abstract
Background: Constitutive expression and localization of antimicrobial human -defensin-1 (HBD-
1) in human kidneys as a potential mechanism of antimicrobial defense has been previously
reported. Inducible expression of human -defensin-2 (HBD-2) has been described in various
epithelial organs but not for the urogenital tract.
Methods: We investigated the gene- and protein expression of HBD-1 and HBD-2 by reverse
transcriptase-polymerase chain reaction, and immunohistochemistry in 15 normal human kidney
samples and 15 renal tissues with chronic bacterial infection. Additionally, cell culture experiments
were performed to study HBD gene expression by real-time RT-PCR in response to inflammatory
cytokines TNF and IL-1 as well as lipopolysaccharide from Gram-negative bacteria.
Results: Constitutive HBD-1 gene- and protein expression was detected in normal renal tissue
and kidneys with chronic infection. As a novel finding, inducible HBD-2 gene- and protein
expression was demonstrated in tubulus epithelia with chronic infection but not in normal renal
tissue. In pyelonephritic kidneys HBD-1 and HBD-2 expression showed a similar pattern of
localizaton in distal tubules, loops of Henle and in collecting ducts of the kidney. Furthermore, real-
time RT-PCR of kidney derived cell lines stimulated with inflammatory agents TNF-, IL-1 and
LPS revealed a strong increase in relative HBD-2 transcription level and also a slight increase in
relative HBD-1 transcription level.
Conclusions: Upregulated HBD-2 expression in renal tubulus epithelium indicates a role of a
wider range of human defensins for antimicrobial host defense in the urogenital tract than
previously recognized.
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Background
Defensins are a family of cationic proteins (3–4 kD) typi-
cally containing 6 cystein residues. Expression of at least
two subfamilies of defensins (- and -defensins) has
been shown in insects, plants and humans in respect to a
difference in the position and connectivity of cystein di-
sulfide bonds [1,2]. The characteristic fold of the protein
molecules is assumed to exercise antimicrobial activity by
selective disruption of microbial membranes. Multimeric
pore formation in the cell membrane of pathogens by an-
timicrobial protein activity is held responsible for the kill-
ing of microorganisms with successive efflux of cellular
contents and breakdown of intracellular homeostasis.
Mammalian cells are thought to be more resistent to this
effect because of a higher content of cholesterol and phos-
pholipids in their membrane. Remarkably, it seems to be
difficult for microorganisms to acquire resistance against
this antimicrobial mechanism, assigning these proteins a
putative role for future therapeutic applications [3].
At least four -defensins (HBD-1, HBD-2, HBD-3, HBD-4)
have been characterized in humans. HBD-1 was first iso-
lated from the hemofiltrate of patients with end stage kid-
ney disease undergoing dialysis, locating renal epithelia as
the major source for HBD-1 [4]. HBD-2 was initially puri-
fied from lesional psoriatic scale extracts by bacteria affin-
ity chromatography and revealed antimicrobial activity
against Gram negative bacteria and yeast like candida [5].
Other localizations of HBD-2 expression include nasal
[6], and oral mucosa [7,8], human airway [9–11], nasol-
acrimal duct [26], and ocular surface epithelium [13] as
well as intestinal epithelium [14] in response to infection
and inflammation. Expression of HBD-3 in psoriatic
scales and human keratinocytes [15] as well as in other ep-
ithelial and non epithelial tissues [12] have been reported
recently. Finally, HBD-4 was identified by screening of ge-
nomic sequences and subsequent functional analysis with
gene expression recognized in testis, stomach, uterus, neu-
trophils, thyroid, lung, and kidney [16].
Former studies have been presented on the expression, lo-
calization and function of HBD-1 in the human urogeni-
tal system [17–20]. Gene expression of HBD-1 was found
by in situ hybridization in the columnar epithelial layers
of the distal tubules, loops of Henle, and collecting ducts
[17]. In contrast immunohistochemical methods stained
only intratubular hyalin substance of the kidney.
At present, only a single investigation mentioned noticea-
ble HBD-2 mRNA expression in one sample of human re-
nal tissue by dot blot hybridization [9]. However,
investigation of HBD-2 gene expression as well as protein
expression in normal human kidneys and in kidneys with
chronic bacterial infection has not yet been systematically
investigated. The present study explores gene expression
and immunohistochemical localization of HBD-1 and
HBD-2 in extirpated kidneys with chronic pyelonephritis
and in normal renal tissue obtained from tumor-bearing
kidneys. Furthermore, in vitro gene expression of HBD-1
and HBD-2 in kidney derived cell lines under proinflam-
matory challenging was investigated.
Methods
Tissue samples
Samples of renal tissue from nephrectomy specimens
were obtained immediately in the operating room and
stored in liquid nitrogen under protocols approved by the
institutional ethics committee. Fifteen renal tissue speci-
mens were obtained from fifteen patients (mean age 60
years – range 12 months to 75 years, 8 female and 7 male
patients) with chronic upper urinary tract infections un-
dergoing nephrectomy. Clinical isolates from preopera-
tively collected urine samples of the 15 patients with
chronic upper urinary tract infection revealed Escherichia
coli in eleven, Klebsiella species in two and Pseudomonas
aeruginosa in two further patients as causative agents. The
etiology responsible for recurrent infection and decline of
renal function were vesicoureteral reflux or obstruction of
the upper urinary tract. The history of recurrent bacterial
infection of the urinary tract usually preceded for a mini-
mum of 10 months with subsequent decline of renal func-
tion before surgical removal of the affected organ was
performed.
Furthermore, histologically confirmed samples of normal
renal tissues were collected from patients who underwent
nephrectomy for a kidney neoplasia (mean age of patients
65 years – range 47 years to 75 years, 8 female and 7 male
patients). In most cases parenchymal architecture of the
kidney was preserved and tissue was dissected into cortex
and medulla before storage in liquid nitrogen.
Corresponding samples of normal and infected renal tis-
sue samples preserved as neutral formalin-fixed and par-
affin-embedded sections were prepared by the
Department of Pathology, University of Kiel. The his-
topathological diagnosis of the tissue samples was inde-
pendently confirmed by two pathologists.
Cell culture
The established human kidney carcinoma cell lines CAKI-
1 and CAL-54 were purchased from the German Collec-
tion of Microorganisms and Cell Cultures (DSMZ, Braun-
schweig, Germany). Cell lines were cultured as a
monolayer in RPMI 1640 medium (Biochrom, Berlin,
Germany) supplemented with 10% heat-inactivated fetal
calf serum (FCS), 2 mmol/L glutamine and 1 mmol/L
pyruvate. Cultures were maintained at a temperature of
37C in a humidified 5% CO2 atmosphere. All cell lines
were routinely tested for mycoplasma contamination us-BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/20
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ing a PCR mycoplasma detection kit (TaKaRa, Biomedical
Europe S.A., Genevilliers, France) and contaminated cell
cultures were discarded.
Proinflammatory in vitro challenging
Confluent cultures were split using trypsin/EDTA and
cells were seeded in 6-well cell culture plates with 9,6 cm2
growth area per well (BD Primaria™, Becton Dickinson,
Heidelberg, Germany). For cell challenging experiments,
cells were grown in FCS free medium for at least 24 hours
to exclude the influence of unknown inhibitory or stimu-
latory FCS compounds on HBD gene expression. Cells
were exposed to inflammatory agents for at least 6 hours.
Inflammatory challenging of the cells was performed us-
ing tumor-necrosis-factor alpha (TNF, Clontech Labora-
tories GmbH, Heidelberg, Germany) or interleukin-1-beta
(IL-1, Biozol GmbH, Eching, Germany) at concentra-
tions between 0.1 and 10 ng/ml or lipopolysaccharide
from Escherichia coli (LPS, Sigma-Aldrich Chemie Gm-
bH, Deisenhof, Germany) at concentrations between 0.1
and 100 g/ml. At the end of the experiment the superna-
tant medium was removed and subsequent extraction of
total RNA of the stimulated cells was performed.
Isolation of total RNA
Total RNA was isolated from cell lines and tissue samples
based on the guanidium-thiocyanate-phenol-chloroform
single-step isolation method [21]. Renal tissue samples
(100–500 mg) were pulverized by mortar and pestel while
being immersed in liquid nitrogen. Total RNA from tu-
mor cell lines was extracted using RNA-Clean™ (AGS-
Chemie Heidelberg, Germany) and total RNA from frozen
tissue specimens was extracted by RNAzol™ (WAK-
Chemie Medical GmbH, Bad Homburg, Germany) as rec-
ommended by the suppliers. To optimize the yield of RNA
extraction, 5 g of glycogen (Roche Boehringer, Mannhe-
im, Germany) were added to the aqueous phase before
precipitation with isopropanol. The RNA preparations
were dissolved in 40 l RNase free water. RNA recovery
and purity were controlled by absorption measurement at
260 nm and 280 nm (Biophotometer, Eppendorf, Ham-
burg, Germany). Samples of 2 g of the extracted total
RNA were separated in 1% agarose gel (Small DNA agar-
ose; Biozym, Hessisch Oldendorf, Germany). The integri-
ty of total RNA was determined by visualising 28S and 18S
ribosomal RNA. Samples with evidence of ribosomal RNA
degradation were discarded.
RT-PCR of tissue samples
An aliquot of 2 g of total RNA of each tissue sample was
dissolved in a volume of 10 l redestillated sterile water,
denatured for 10 min at 70C and then quickly chilled on
ice. The cDNA was synthesized in a total volume of 20 l
containing 4 l 5 first-strand buffer, 2 mM dithiothreitol
(DTT), 200 U of SuperScript II (all Life Technologies, Egg-
enstein, Germany), 20 U of RNase inhibitor, 5 M ran-
dom hexamers, 1 mM deoxynucleotide triphosphate
(dNTP) mix (all Applied Biosystems GmbH, Weiterstadt,
Germany). The reaction mix was incubated for 10 min at
24C and 60 min at 42C. Reverse transcriptase was then
inactivated for 3 min at 94C.
HBD-1 and HBD-2 PCR of tissue samples
Primers for HBD-1 sense,
5'-ATGAGAACTTCCTACCTTCTGCT-3',  and 
HBD-1 antisense, 5'-CTCTGTAACAGGTGCC-3', 
resulted in a 184-bp fragment. Primers for HBD-2 sense, 
5'-CCAGCCATCAGCCATGAGGGT-3', and
HBD-2 antisense, 5'-GGAGCCCTTTCTGAATCCGCA-3',
resulted in a 255-bp fragment. Primers for the housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) sense, 5'-CCAGCCGAGCCACATCGCTC-3' and
GAPDH anti-sense, 5'-ATGAGCCCCAGCCTTCTCCAT-3'
were added to each specific human -defensin PCR reaction
mix to monitor correct cDNA synthesis. GAPDH PCR resulted
in a 359-bp fragment (GAPDH primer-sequences kindly
provided by Dr. C. Schlüter, Department of Dermatology,
University of Kiel, Germany). All primers were commercially
synthesized (MWG-Biotech, Ebersberg, Germany).
For specific HBD-1 or HBD-2 RT-PCRs 5 l of the cDNA
synthesis mix were used in 50 l of the final reaction mix,
which contained 5 l of 10 tricine buffer III, 200 M de-
oxynucleotide triphosphate mixture, 1.5 M of human -
defensin sense and 1.5 M of human -defensin antisense
primer as well as 0.15 M of GAPDH sense and 0.15 M
of GAPDH antisense primer. One unit of Taq-DNA-
polymerase (Gibco BRL Life Technologies, Eggenstein,
Germany) was added to the reaction mix after denaturing
cDNA at 95C for 5 min (Table 1) in a thermocycler (Bi-
ometra, Göttingen, Germany). Thirty PCR cycles were per-
formed.
Two g of total RNA from nasal epithelium which has
been stimulated by bacterial lipopolysaccharide in vitro
was used as a positive control for HBD-1 and HBD-2 RT-
PCR. The absence of contamination was routinely
checked by RT-PCR assays of negative samples, in which
RNA samples were replaced with sterile water (water con-
trol) and by omitting SuperScript II. All RT-PCR products
were separated by electrophoresis in a 2% agarose gel
(Small DNA agarose, Biozym, Hessisch Oldendorf, Ger-
many) in Tris-acetate-EDTA (TAE)-buffer and visualized
by ethidium-bromide staining. Molecular weights were
determined using a DNA molecular-weight marker (100-
bp DNA ladder, Life Technologies, Eggenstein, Germany).
Representative fragments of specific HBD-1 and HBD-2
RT-PCRs were extracted from agarose gels by QIAEX II Gel
Extraction-Kit (QIAGEN GmbH, Hilden, Germany). TheBMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/20
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isolated cDNA product was sequenced by an automatic se-
quencer ALFexpress (Pharmacia, Freiburg, Germany).
Real-time RT-PCR of stimulated cell lines
Real-time RT-PCR analyses were performed in a fluores-
cence temperature cycler (LightCycler, Roche Molecular
Biochemicals) according to the manufacturer's instruc-
tions. This technique continuously monitors the cycle-by-
cycle accumulation of fluorescently labeled PCR product.
Briefly, total RNA from cultured epithelial cells was isolat-
ed and reverse transcribed as described above. The cDNA
corresponding to 20 ng RNA served as a template in a 20
l reaction containing 4 mM MgCl2, 0.5 M of each prim-
er and 1 LightCycler-FastStart DNA Master SYBR Green I
mix (Roche Molecular Biochemicals). Samples were load-
ed into capillary tubes and incubated in the fluorescence
thermocycler (LightCycler) for an initial denaturing at
95C for 10 min followed by 45 cycles, each cycle consist-
ing of 95C for 15 s, 60C (touchdown of -1C/cycle from
66C to 60C) for 5 s and 72C for 10 s. Cycle-to-cycle flu-
orescence emission readings were monitored at 72C at
the end of each cycle and analyzed using LightCycler Soft-
ware (Roche Molecular Biochemicals). Melting curves
were generated after each run (cooling the sample to 65C
for 15 s and then heating slowly at 0.2C/s up to 95C
with continuous measurement of fluorescence) to con-
firm amplification of specific transcripts.
Amplification was carried out using gene specific, intron-
spanning primers for HBD-1 and HBD-2 (HBD-1 sense:
5'-TTGTCTGAGATGGCCTCAGGTGGTAAC-3', HBD-1
antisense: 5'-ATACTTCAAAAGCAATTTTCCTTTAT-3';
HBD-2 sense: 5'-ATCAGCCATGAGGGTCTTGT-3', HBD-2
antisense: 5'-GAGACCACAGGTGCCAATTT-3'). Amplifi-
cation of the housekeeping-gene GAPDH was performed
with each cDNA in a separate PCR-reaction using intron-
spanning primers GAPDH sense: 
5'-CCAGCCGAGCCACATCGCTC-3' and GAPDH anti-
sense: 5'-ATGAGCCCCAGCCTTCTCCAT-3'. Relative
HBD-1 and HBD-2 transcript levels were corrected by nor-
malization based on the GAPDH transcript levels. Specif-
icity of HBD-1 and HBD-2 encoding PCR products was
verified by agarose gel electrophoresis and by sequencing
of representative samples.
HBD-1 and HBD-2 immunohistochemistry
All sections were cut from formalin-fixed and paraffin-em-
bedded specimens at a thickness of 5 m and mounted on
adhesive slides (HistoBond slides, Marienfeld Glassware,
Bad Mergentheim, Germany). The sections were depar-
affinized (twice in Xylol, twice in 100%, 96%, and 70%
Ethanol, twice in redestillated sterile water for 15 min
each).
Antigenic epitopes were demasked by boiling sections for
2 min in citratbuffer (2.1 g citrat in 1 liter of redestillated
sterile water at pH 6) in a pressure cooker. Sections were
rinsed with redestillated sterile water and then treated
with 0.5% hydrogen peroxide in methanol for 30 min to
block endogenous peroxidase activity. Sections were rehy-
drated and washed in phosphate-buffered saline (PBS) be-
fore blocking with 5% of normal goat serum (Dako,
Table 1: Cycling protocol for HBD-1, HBD-2 and GAPDH RT-PCR
Step Denaturation time/temperature Annealing time/temperature Extension time/temperature Number of cycles
HBD-1
1 1 5 min/95C 30 sec/55C 30 sec/72C1
2 30 sec/95C 30 sec/55C 30 sec/72C2 8
3 30 sec/95C 30 sec 55C 10 min/72C1
HBD-2
1 1 5 min/95C 30 sec/60C 30 sec/72C1
2 30 sec/95C 30 sec/60C 30 sec/72C2 8
3 30 sec/95C 30 sec/60C 10 min/72C1
2 GAPDH
1 5 min/95C 30 sec/55C or 60C 30 sec/72C1
2 30 sec/95C 30 sec/55C or 60C 30 sec/72C2 8
3 30 sec/95C 30 sec/55C or 60C 10 min/72C1
1 Taq Polymerase added at the end of the first 5 min denaturation step. 2GAPDH RT-PCR was performed as duplex PCR in concert with either 
HBD-1 or HBD-2BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/20
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Hamburg, Germany) in PBS and then incubating with avi-
din and biotin for 15 min. HBD-1 and HBD-2 polyclonal
rabbit anti-serum (kindly provided by Tom Ganz, Erika
Valore and Lide Liu, UCLA, USA) were diluted 1:500 in
PBS. Sections were incubated for 1 h at room temperature
and then washed several times in PBS and treated with bi-
otinylated anti-goat immunoglobuline G (Dako, Ham-
burg, Germany). Sections were further incubated with
solution of avidin-biotinylated peroxidase complex (Vec-
tor laboratories Inc., Burlingame, USA). Reactions were
developed with 0.02% hydrogen peroxide and 0.1% di-
aminobenzdine tetrahydrochloride for 5–10 min. Sec-
tions were then counterstained with Harris modified
hematoxylin (Merck, Darmstadt, Germany) for 1–3 min.
Negative control sections were incubated with preim-
mune serum from the same rabbit as the polyclonal anti-
body was generated from. The immunoreactivity was
graded based on the staining intensities above that seen
on the negative controls. (1+ weak; 2+ moderate; 3+
strong). Staining of moderate and strong intensity were
considered positive. Representative areas were evaluated
estimating the percentage of histoanatomical structures
stained and results were confirmed independently by two
pathologists.
Figure 1
HBD-1 and HBD-2 specific RT-PCR of normal renal parenchyma and renal tissues with chronic infection. HBD-1 (Fig. 1a) spe-
cific RT-PCR (PCR product: 184 bp), HBD-2 (Fig. 1a) specific RT-PCR (PCR product: 255 bp). Samples were separated by 2%
agarose gel electrophoresis and stained with ethidium bromide. Representative data from a panel of 30 specimens are pre-
sented. Lanes 1 to 10 represent renal tissue extracts with chronic infection. Lanes 11–20 show RT-PCR results of normal renal
tissue extracts from tumor-bearing organs. Outer lanes (M) represent a 100 bp-ladder molecular-weight marker. The control
reaction for correct cDNA synthesis in all samples was performed as RT-PCR for GAPDH (glyceraldehyde-3-phosphate dehy-
drogenase) yielding a 359 bp product. Correct positive and negative controls including amplification without reverse transcrip-
tion or cDNA sample replaced by sterile water were performed with each original experiment but are not shown due to
limited gel space.BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/20
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Results
RT-PCR of HBD-1 and HBD-2 in tissue samples
HBD-1 RT-PCR was positive in all 30 investigated samples
of normal and chronically infected renal tissues showing
a distinct band migrating as 184 bp product on 2% agar-
ose gel electrophoresis. HBD-2 RT-PCR was positive in 14
out of 15 samples extracted from renal tissues with chron-
ic bacterial infection yielding a 255 bp band. In contrast,
HBD-2 RT-PCR was negative in all 15 normal kidney tis-
sue extracts without infection from tumor bearing organs.
The control for correct cDNA synthesis performed as GAP-
DH RT-PCR was positive in all samples as well as in HBD-
1 and HBD-2 expressing positive controls of lipopolysac-
charide stimulated nasal epithelium (Fig. 1).
Immunolocalization of HBD-1 and HBD-2 peptide in renal 
tissue sections
Immunohistochemical staining with polyclonal rabbit
antiserum against HBD-1 and HBD-2 was performed on
formalin-fixed and paraffin-embedded renal tissue sec-
tions with chronic bacterial infection and normal renal
parenchyma from tumor bearing organs. Bright-field mi-
croscopy demonstrated HBD-1 protein expression in all
investigated specimens. There was no obvious difference
noted in amount or intensity of staining in sections of
normal and chronically infected kidneys. About 20 to 30
percent of distal tubules, loops of Henle and collecting
ducts in all investigated tissue sections displayed generally
strong HBD-1 cytoplasmatic staining (Fig. 2a). Positively
stained structures were scattered across renal cortex and
medulla localized right next to entirely negative neph-
rons. Generally, all glomerula and proximal tubules were
negative for HBD-1 immunostaining. Negative controls
incubated with preimmune serum showed no staining re-
action (data not shown). In contrast, HBD-2 polyclonal
antibody stained only sections from chronically infected
tissue samples but no samples of normal renal tissue. In
chronically infected samples HBD-2 antiserum stained
distal tubules, loops of Henle and collecting ducts
throughout cortex and medulla (Fig. 2b). Similar to HBD-
1 staining patterns HBD-2 immunostaining were scattered
across the section often localized next to corresponding
parts of the nephron with no staining. Glomerula and
proximal tubules were generally negative. Tissue sections
from normal kidney samples showed no immunostaining
with HBD-2 antiserum (Fig. 2c).
HBD-1 and HBD-2 real-time RT-PCR in stimulated cell 
lines
As an unexpected finding, proinflammatory agents led to
an increase of the relative transcription levels of HBD-1
which were corrected by normalization based on the GAP-
DH transcript levels (Fig. 3a,3b,3c). A 15-fold relative
transcription level was noted when incubating CAKI-1 or
CAL-54 with 10 ng/ml of TNF compared to 1-fold in un-
stimulated controls or 3-fold when incubating with 0.1
ng/ml of TNF. This observation was also confirmed for
IL-1 and LPS stimulation to a lesser extent (Fig. 3b,3c).
As expected relative HBD-2 transcript levels increased
strongly by addition of TNF, IL-1, and moderated in-
crease was noted under LPS stimulation (Fig. 4a,4b,4c).
The highest relative transcription level (476) was noted
when incubating CAL-54 cells for 6 hours with 10 ng/ml
of IL-1 (Fig. 4b), while incubating with the same amount
of TNF (Fig. 4a) resulted in a relative transcription level
of (82). A concentration of 100 g/ml of LPS from Es-
cherichia coli led to a slight increase in relative transcrip-
tion levels (15) when compared to negative controls
(Fig. 4c).
Sequencing of representative fragments of HBD-1 and
HBD-2 specific RT-PCR proved 100% identity with
known sequences from the GenBank nucleotide database
(GenBank Accession No. X92744 and Z71389).
Discussion
Antimicrobial proteins are widely distributed constituents
of innate host defense in animals and plants. Of the many
known characteristic defensins which exert antimicrobial
activity, -defensins have been found only in vertebrates
including mammals and birds [3]. Three authors have
studied profoundly the expression and functional aspects
of HBD-1 in urine and normal human kidneys [17,19,20].
In agreement with Valore's et al. investigation on HBD-1
gene expression we found constitutive HBD-1 gene ex-
pression in all examined tissue samples of normal kidneys
as well as chronically infected renal specimens by RT-PCR.
Albeit, in our immunostaining experiments we were able
to visualize about 30 percent of positive distal tubules,
Henle's loops and collecting ducts, contradicting Valore's
immunostaining studies where only intraluminal hyalin
substance in the renal tubulus would stain with HBD-1
antiserum [17]. Comparison of immunostaining and in
situ hybridization results using digoxigenin labeled cDNA
probes (data not shown) revealed corresponding patterns
of positive protein and gene expression in histoanatomi-
cal structures such as distal tubules, Henle's loops and col-
lecting ducts, whereas glomerula and proximal tubules
were always non-reactive with either cDNA probes or pol-
yclonal antiserum.
Valore and coworkers [17] observed interindividual varia-
bility of quantitative HBD-1 protein levels between 10 to
100 g/l in urine from eight different donors. This led the
authors to speculate about altenative forms of physiologic
regulation of HBD-1 synthesis by non-classical immunos-
timulants such as estrogen and progesterone which were
reported to modulate the concentration of antimicrobial
lactoferrin and lysozyme [22,23]. In agreement with thisBMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/20
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Figure 2
Immunostaining of formalin-fixed and paraffin-embedded sections of chronically infected kidneys with polyclonal rabbit anti-
serum for HBD-1 (Fig. 2a) and HBD-2 (Fig. 2b). Strong cytoplasmatic staining by HBD-1 immunohistochemistry was experi-
enced in 20 to 30 percent of distal tubules, loops of Henle and collecting ducts in all normal and chronically infected tissue sec-
tions. All glomerula and proximal tubules were negative for HBD-1 immunostaining. HBD-2 polyclonal antibody stained only
sections from chronically infected tissue samples with moderate to strong intensity in distal tubules, loops of Henle and collect-
ing ducts (Fig. 2b). Glomerula as well as proximal tubules showed no staining. Fig. 2c shows negative staining with preimmune
rabbit serum.BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/20
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hypothesis Valore and coworkers noted the highest HBD-
1 concentrations in urine from pregnant women and gen-
erally lower levels of HBD-1 in men than in women.
When exploring this observation in vitro, we could not de-
tect any differences in HBD-1 gene expression after stimu-
lating CAL-54 and CAKI-1 cell lines with increasing
concentrations of estrone, -estradiol, estriol, progester-
one, chorionic gonadotropin, or lactogen alone or in
combination over variable lengths of time (data not
shown).
Hiratsuka et al. [19] saw an average 3.1-fold increase in
urinary HBD-1 concentration from 8 patients with
pyelonephritis as compared to controls by radioimmu-
noassay, which support our real-time RT-PCR results of
slightly inducible HBD-1 expression in vitro (Fig.
3a,3b,3c). However, when investigating HBD-1 gene ex-
pression in tissue samples by real-time RT-PCR our results
where inconclusive with some pyelonephritic samples re-
vealing a higher relative HBD-1 transcript level and others
not compared to normal renal tissue samples (data not
shown).
In the immunohistochemical experiments of our study we
were also not able to detect obvious interindividual differ-
ences in respect to the quantity and intensity of HBD-1 re-
activity. HBD-2 became known as the first human
defensin that is expressed by epithelial cells after contact
with microorganisms or proinflammatory cytokines [24]
but at present no systematic investigation of HBD-2 ex-
pression in renal tissue has been performed so far. Current
studies revealed no basal rates of HBD-2 gene and pro-
tein-expression in normal human kidney, salivary gland,
small intestine or liver [5], except one study by Bals and
Figure 3
Cultured CAL-54 cells were stimulated with increasing
TNF (Fig. 3a), IL-1 (Fig. 3b), and LPS (Fig. 3c) concentra-
tions for 6 hours in FCS-free medium. HBD-1 mRNA
expression was analyzed by real-time RT-PCR. Bars repre-
sent the relative HBD-1 transcript levels normalized to
GAPDH transcript levels.
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Figure 4
Cultured CAL-54 cells were stimulated with increasing
TNF (Fig. 4a), IL-1 (Fig. 4b), and LPS (Fig. 4c) concentra-
tions for 6 hours in FCS-free medium and HBD-2 mRNA
expression was analyzed by real-time RT-PCR. Bars repre-
sent the relative HBD-2 transcript levels normalized to
GAPDH transcript levels.
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co-workers reported HBD-2 mRNA expression in kidney
extracts by dot blot hybridization using a commercially
available filter [9].
As a novel finding in our study, induced gene- and protein
expression of HBD-2 was detected in 14 out of 15 chroni-
cally infected kidneys in contrast to negative expression in
normal non-infected renal tissue from tumor bearing kid-
neys. Similar qualitative HBD-2 gene expression was
found in infected kidneys with either Escherichia coli,
Klebsiella or Pseudomonas species as the causative patho-
gen for chronic bacterial kidney infection. These results
were supported by cell culture studies that found upregu-
lated HBD-2 gene expression in kidney-tumor derived cell
lines CAL-54 and CAKI-1 after incubation with various
proinflammatory stimuli such as TNF, IL-1, and higher
LPS concentrations from Escherichia coli.
Our cell culture studies revealed inducible HBD-2 gene ex-
pression by TNF, IL-1 and higher LPS concentrations
from Escherichia coli. These results parallel previous find-
ings of upregulated HBD-2 mRNA expression in cultured
keratinocytes from human skin [5] airway epithelium
[10,11]. and oral mucosa [8] by proinflammatory cy-
tokines [7]. In contrast to kidney-tumor derived cell lines
CAL-54 and CAKI-1 the immortalized embryonal kidney
cell line HEK-293 could not be activated by LPS or cy-
tokines in our experiments (data not shown) which has
also been previously noted by Brightbill et al. [25]
Conclusion
Similar to other epithelial systems of the human body ep-
ithelium, nephrons of human kidney have the capacity to
produce a variety of different gene encoded antimicrobial
proteins. These proteins may mount an immediate first
line response against microbial pathogens before cellular
and humoral defense mechanisms become effective at a
later time. Although HBD-1 gene expression has been
considered constitutive only, our in vitro results further
support the observation of others that HBD-1 may also
underlie regulation by proinflammatory cytokines or oth-
er unidentified factors to a noteworthy extent.
Further prospects for studies on human beta defensin ex-
pression and regulation in the uro-genital context include
investigation of urothelium of the urinary bladder, pros-
tatic glands and epithelia from female and male reproduc-
tive tracts under normal and inflammatory conditions as
well as defining the role of the recently published HBD-3
[12,15]. and HBD-4 [16] within the urogenital tract.
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